The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has commenced a new review regarding its prior decision to not approve Eli Lilly’s Alzheimer’s medication, Kisunla. This fresh evaluation of donanemab, marketed under the brand name Kisunla, was initiated on June 2 following a request from Eli Lilly. Detailed information regarding this process was revealed in the committee’s monthly meeting summary, released on Friday.
Initially, the CHMP had recommended against granting marketing authorization for the Alzheimer’s treatment within the European market. However, this re-examination process offers Eli Lilly another chance for Kisunla to gain approval for use in Europe, potentially overturning its earlier rejection.
Yorum Yap